1.1.3 Immunosuppressants

Click Here for Kent and Medway Health Economy National Tariff Excluded Drugs Manual -High Cost Drugs

Etrasimod (Velsipity^®)	This High-Cost Drug has been approved for the following indications: - for treating moderately to severely active ulcerative colitis in people aged 16 and over when: •conventional or biological treatments cannot be tolerated or •the condition has not responded well enough, or lost response to treatment. as per NICE TA956.
For more information and NICE Guidance Click Here	Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over NICE TA956 ICB commissioned - approval via Blueteq

Infliximab biosimilar (Flixabi^®)

This High-Cost Drug has been approved for the following indications: - for treating

adults with severe active Crohn's disease whose disease has not responded to conventional therapy and people aged 6–17 years with severe active Crohn's disease whose disease has not responded to conventional therapy as per NICE Guidance
moderately to severely active ulcerative colitis after the failure of conventional therapy as per NICE Guidance

For more information and NICE Guidance Click Here

Infliximab and adalimumab for the treatment of Crohn's disease in adults, and Infliximab, within its licensed indication, is recommended for the treatment of people aged 6–17 years with severe active Crohn's disease whose disease has not responded to conventional therapy NICE TA187
ICB commissioned - approval via Blueteq (Adults) NHSE commissioned - (Paediatrics 6 - 17)

Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy NICE TA329
ICB commissioned - approval via Blueteq

Mirikizumab (Omvoh^®)	This High-Cost Drug has been approved for the following indications: - for treating moderately to severely active ulcerative colitis in adults as per NICE Guidance
For more information and NICE Guidance Click Here	Mirikizumab for treating moderately to severely active ulcerative colitis NICE TA925 ICB commissioned - approval via Blueteq

Ozanimod	This High-Cost Drug has been approved for the following indications: - Ozanimod (Zeposia) for treating moderately to severely active ulcerative colitis in adults only if: when conventional or biological treatments cannot be tolerated or are not working well enough, and infliximab is not suitable, and the company provides it according to the commercial arrangement.
For more information and NICE Guidance Click Here	Ozanimod for treating moderately to severely active ulcerative colitis NICE TA828 ICB commissioned - approval via Blueteq

Risankizumab - SKYRIZI^®	This High-Cost Drug has been approved for the following indications: - Treatment of previously treated moderately to severely active Crohn’s disease
For more information and NICE Guidance Click Here	Risankizumab for previously treated moderately to severely active Crohn's disease NICE Guidance TA888 ICB commissioned - approval via Blueteq (Adults) NHSE commissioned - (Adolescents 16 - 17)

Upadacitinib	This High-Cost Drug has been approved for the following indications: - Treatment of moderately to severely active ulcerative colitis in adults: when conventional or biological treatment cannot be tolerated, or if the condition has not responded well enough or has stopped responding to these treatments as per NICE Guidance Treatment of previously treated moderately to severely active Crohn’s disease
For more information and NICE Guidance Click Here	Upadacitinib for treating moderately to severely active ulcerative colitis NICE Guidance TA856 ICB commissioned - approval via Blueteq
For more information and NICE Guidance Click Here	Upadacitinib for previously treated moderately to severely active Crohn’s disease NICE Guidance TA905

First Line Choice
On Formulary
Specialist Initiation Only

Hospital Only
KMPT Initiation Only